Qualigen Files US Application To Start Human Trials For COVID-19 Candidate

Qualigen Therapeutics Inc QLGN has submitted an Investigational New Drug (IND) application to the FDA for its QN-165 with an initial target indication of COVID-19 in hospitalized patients.
QN-165, a DNA aptamer, is a broad-based antiviral drug candidate that has exhibited antiviral activity in multiple in vitro assays against different viruses.
Price Action: QLGN shares are up 10.1% at $1.96 during the premarket session on the last check Wednesday.
Related content: Benzinga's Full FDA Calendar.